CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.…
Industry Peers
BiotechnologyKey Statistics
About Corcept Therapeutics (NASDAQ: CORT)
›
Corcept Therapeutics (NASDAQ: CORT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 730 employees.
The shares were at 63.62 USD on 20 November 2026, down 13.7% over 52 weeks. Its 52-week range is 28.66 USD to 124.01 USD: the price is 48.7% below the high and 122.0% above the low.
At a market capitalisation of 6.96B USD, it trades at 47.8 times trailing earnings and 12.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 44% for CORT.
Corcept Therapeutics reports return on equity of 15.4%, an operating margin of 11.5% and revenue up 64.0% year over year.
It holds more cash than debt, a net cash position of 361.71M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 142.60 USD is 124.1% above the current price. The next earnings report is expected on 24 February 2027.